Revolutionizing “End Stage Renal Disease”
Dear Investor, in a collaborating joint effort with Dr. Vincent Anthony, MD, MPH, MBA, FASN, CHCQM, CPE and President/CEO K.Care MSO/K.Care IPA, we are thrilled to introduce you to K.Care MSO, the administrative arm and holding company of K.Care IPA, an organization poised to redefine End Stage Renal Disease (ESRD) care within managed care environments.
Our Overall Mission Objectives:
K.Care IPA was founded with the vision of creating a network of exceptional Nephrologists dedicated to providing high-quality ESRD services to patients of managed care organizations and special needs programs. Through collaborative efforts with HMOs, Accountable Care Organizations (ACOs), FQHCs, and Full-Service/Primary Care IPAs, we aim to elevate the efficiency and effectiveness of ESRD care for the populations they serve.
Our Unique Area of Focus Approach:
At the core of our service offering are our Nephro-Extensivists, who serve as both the Primary Care Physician and the Nephrologist for ESRD patient-members. This innovative model ensures seamless and comprehensive care, forming the foundation of our commitment to excellence.
An Ever-Expanding Market Opportunity:
Traditionally, managing medically complex, high-cost ESRD patients has presented challenges for the managed care market. Currently, only 14% of ESRD patients are enrolled in Medicare Advantage plans.
With the recent passage of the 21st Century Cures Act of 2016, this landscape is set to shift dramatically, with an estimated 41% of all ESRD patients projected to enroll in these plans over the next four years. Given the penetration of managed care in the California market, this proportion will approach 65%.
Joint Venture Investment Offering:
We are offering up to $4.0 million in subordinated convertible promissory notes, with the goal of raising between $3.0 million and $4.0 million. Multiple closings may occur, and the minimum investment is $250,000, which may be waived by the Company.
Pin-Point Use of Funds:
The raised capital will be allocated towards working capital, growth initiatives, general corporate purposes, and expenses related to the financing <===(See Attached Terms Here)===>.
Additional Information:
- In case of a Non-Qualified Equity Financing, investors may choose to convert their Notes into Shadow Preferred units.
- If the Company issues new debt convertible into equity with more favorable terms than the Initial Notes, the Initial Notes may be amended.
- Investors must be accredited investors.
- The terms and existence of the Term Sheet are confidential and should not be disclosed without the Company’s consent.
In our collaborative joint venture, we believe K.Care IPA represents a significant opportunity to reshape ESRD care. Your investment in K.Care MSO will not only contribute to this mission but also align you with an organization dedicated to making a meaningful impact on the lives of countless patients.
In representation of the K.Care MSO, thank you for considering this opportunity. We look forward to further discussions. For any immediate questions or if you’d like to schedule some time to speak with Dr. Anthony, please contact K.Care IPA’s Executive Secretary, Dorothy Huynh at: (714) 249-0915 email: dorothy@kcareipa.com or visit: kcareipa.com
The West Athens Westmont Task Force Team